TP-110 

TP-110 is a proteasome inhibitor. TP-110 specifically inhibits the protease-like activity of the 20S proteasome, but does not affect the trypsin-like or peptidyl-glutamyl peptide hydrolysis activity. TP-110 inhibits the NF-κB pathway, activates caspase-8, -9, and -3, and causes PARP cleavage, significantly reducing the levels of cIAP-1 and XIAP. TP-110 causes cell cycle arrest at the G2/M phase and promotes apoptosis of cancer cells. TP-110 can be used in cancer research of prostate cancer and multiple myeloma, etc^[1][2].

623.74

C₃₇H₄₁N₃O₆

688737-95-3

CC([C@@H](C(N)=O)N(C([C@H](CC1=CC=C(C=C1)OC)NC(CC2=C3C=CC=CC3=CC=C2)=O)=O)C(CC4=CC=C(C=C4)OC)C=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Iijima M, Momose I, Ikeda D. TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells. Anticancer Res. 2009 Apr;29(4):977-85.

  [2]. Momose I, et al. A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells. Biosci Biotechnol Biochem. 2007 Apr;71(4):1036-43.